Skip to main content

Part of UT Health San Antonio

Office of the Vice President for Research - UT Health San Antonio Office of the Vice President for Research - UT Health San Antonio

Part of the Office of the Vice President for Research

Quicklinks

Quicklinks

Human Study Submissions

  • Research Approval Process
  • Clinical Trial
  • UTHSA IRB Review
  • External IRB Review
  • VA Human Research
  • Amendment/Modifications
  • Personnel Change
  • Progress Report/Update Report
  • Prompt Report
  • Exception Request

Logins

  • ORCA
  • Velos
  • iDisclose
  • CITI
  • ERMS Resources
  • iLab

Events

  • Concierge Services
  • Upcoming Events

Find

  • Training for Animal Studies
  • Training for Human Studies
  • Glossary
  • Forms
  • Guidance & Policies
  • Trending Information
  • VPR IT-Application Support

Contact Us

  • IRB
  • OCR-VA
  • CTO
  • ARC
  • LAR
  • VPR IT
  • OSP
  • OTC
  • VPR IT

More

  • Investigator Registry
  • Find-A-Study
  • EMR Monitoring Request
  • Close Quicklinks

Menu
  • Home
  • Development
  • Logistics
  • Approval
  • Initiation
  • Management
  • Close Out
  • Offices
  • VPR

You are here

  • Home
  • University
  • VPR
  • Services
  • Approval
  • The Human Study Lifecycle
  • Treatment Use/Expanded Access Use of Drug/Device

Treatment Use/Expanded Access Use of Drug/Device

Expanded accessExpanded Accessuse of an investigational (unapproved) drug or device when the primary purpose is to diagnose, monitor, or treat a patient's disease or condition. The distinction between expanded access and the use of an investigational drug (or device) in research covered under an IND/IDE is that expanded access uses are not primarily intended to obtain information about the safety or effectiveness of a test article. Although not considered research, the FDA requires IRB approval prior to non-emergency use.   to investigational drugs for treatment use is available when the local investigator or sponsorSponsorare the agencies, institutions, companies, organizations, foundations, or individual grantors responsible for the initiation, management, or financing of a research study.   applies to the FDAFDAabbreviation for US Food and Drug Administration.  and the IRB for: 1) individual patients (including in emergencies); 2) intermediate size patient populations; and 3) larger populations under a treatment protocolProtocolstep-by-step details of how a study will be conducted including objectives, design, procedures, measurements, management and analysis, as well as a discussion of relevant research ethics issues.  or treatment investigational new drugInvestigational New Drug(or IND) an application filed with the FDA that includes a detailed description of the planned investigation including Phase I, II and III studies.   application ( INDINDInvestigational New Drug application with the FDA.   ).  Expanded Access/Treatment Use is intended to improve access to investigational drugs for patients with serious or immediately life-threateningLife-threateningdiseases or conditions where the likelihood of death is high unless the course of the disease is interrupted.   diseases or conditions who lack other therapeutic options and who may benefitBenefitsomething that promotes or protects well-being, an advantage. Compensation cannot be considered a benefit.   from such therapies. Requires prior IRB approval, but is not considered researchResearcha systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.   . Requires an IND/ IDEIDEInvestigational Device Exemption filed with the FDA   from FDA. 

Submit the following forms to IRBmail@uthscsa.edu for IRB review and approval:

  • Form tA - Signature Assurance Sheet (Please note: Assure that both the PI and the PI’s chair sign this form or we will not be able to accept the submission.  The PI cannot be the same as the chair due to the conflict of interestConflict of Interestrefers to situations where the individual has the opportunity to influence the Health Science Center's business, administrative, academic, research, clinical, or other decisions in ways that could lead to personal financial gain or advantage or could appear to cause bias in the design, conduct, or reporting of research or educational activities.   that presents.)
  • Form tB - General Information Sheet
  • Form tB-2 - Study Personnel List
  • Form tC - Research Description (For use if no summary letter or treatment protocol has yet been created for submission to the FDA, otherwise replace this form with a copy of the FDA submission package.)
  • Form t-Inst - Institutional Treatment Form

And, if applicable:

  • Form tD - Research Consent
  • Form tO - Use of a Drug in Research
  • Form tO-1 - Use of Approved Drug(s) for Unapproved Use
  • Form tP - Use of Investigational Device Form

Need Help?

Contact the OIRB

210-567-8250

IRB@uthscsa.edu

 

Map image of UT Health San Antonio location

UT Health San Antonio

8403 Floyd Curl Dr
San Antonio, TX 78229

210-567-7028
vpr@uthscsa.edu

Connect with us

  • Twitter
  • YouTube
  • Linked In
  • Job Opportunities
  • Research Directory
  • Give a Donation

We make lives better ®

The University of Texas Health Science Center at San Antonio, also called UT Health San Antonio, is a leading academic health center with a mission to make lives better through excellence in advanced academics, life-saving research and comprehensive clinical care including health, dental and cancer services.

Web Privacy | Links from websites affiliated with UT Health's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.